Valacyclovir: Difference between revisions
(special populations) |
(pharmacology) |
||
| Line 49: | Line 49: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: < 30 minutes | ||
*Metabolism: | *Metabolism: GI tract, liver | ||
*Excretion: | *Excretion: feces, urine | ||
*Mechanism of Action: | *Mechanism of Action:inhibits DNA polymerase | ||
==See Also== | ==See Also== | ||
Revision as of 21:31, 2 April 2015
General
- Type: inhibits DNA polymerase
- Dosage Forms: 500, 1000
- Common Trade Names: Valtrex
Adult Dosing
HSV-1
- Acute episode: 2000 mg PO BID x 1 day
- Suppression: 500 mg PO Qday
Genital HSV
- 1st episode: 1000 mg PO BID x 7-10 days, start within 48-72 hour of symptoms
- recurrence: 500 mg PO BID x 3 days, alternative: 1000 mg PO qday x 5 days
Shingles
- 1000 mg PO TID x 7 days
Pediatric Dosing
Genital HSV
- same as adult dosing for adolescents
Special Populations
- Pregnancy Rating: B
- Lactation: safe
- Renal Dosing
- Adult:
- Pediatric
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- caution if renal impairment
Adverse Reactions
Serious
- acute renal failure
- thrombocytopenia
- aplastic anemia
- delirium
- psychosis
- seizures
Common
- nausea/vomiting
- headache
- abdominal pain
- depression
- elevated LFT's
- fatigue
Pharmacology
- Half-life: < 30 minutes
- Metabolism: GI tract, liver
- Excretion: feces, urine
- Mechanism of Action:inhibits DNA polymerase